PulseAugur
EN
LIVE 12:19:10
中文(ZH) 美诺华:拟定增募资不超21.09亿元,用于高活性制剂及难溶性药物高端研发等项目

Meinuo Hua to raise 2.1B yuan for drug R&D and production

Meinuo Hua plans to raise up to 2.109 billion yuan through a private placement of shares. The funds will be allocated to projects including a global industrial base for high-end oral solid preparations and complex injections, as well as an R&D initiative for high-activity and poorly soluble drugs. A portion of the capital will also be used to supplement working capital. AI

IMPACT This funding will support R&D in advanced drug formulations, potentially leading to new therapeutic options.

RANK_REASON Company funding round announcement. [lever_c_demoted from significant: ic=1 ai=0.4]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Mino Pharma: Plans to raise no more than 2.109 billion yuan through private placement for high-activity preparations and high-end R&D for poorly soluble drugs projects

    36氪获悉,美诺华公告,公司拟向特定对象发行股票募资不超过21.09亿元,扣除发行费用后用于高端口服固体制剂和复杂注射剂全球化产业基地项目、高活性制剂及难溶性药物高端研发项目、补充流动资金。